Vivi Wang

Vivi Wang is a results-driven professional with 19 years of experience in pharmaceutical in-/out-licensing, pipeline valuation, commercialization, and pricing & market access. They have successfully launched multiple new molecular entities (NMEs) and indications across various therapeutic areas, including oncology and immunology, while closing over 20 significant licensing and partnership deals totaling more than $10 billion. Vivi has held key roles at esteemed companies such as EY, Eli Lilly, Shire, AstraZeneca, and IQVIA, and earned an MBA from the Tuck School of Business at Dartmouth College.